Ann: EYE February sales update, page-41

I did have a look, not much to take away except that they're struggling a bit to grow, probably due to a competitor named Nova Eye taking all their customers! They still recorded 18% growth for the year, but as we know that's quite low when it comes to the high growth MIGS market (in the US at least). They did say that the MIGS market appears to be more alive than ever though after the LCD news, with a major focus this year at the AGS conference being on "interventional glaucoma management" - the idea that doctors should intervene earlier in the disease stage with MIGS rather than decades of eye drops. This trend is quite exciting as interventional glaucoma management basically means we should be aiming to replace drops with MIGS, and as we know the eye drops market is a massive market worth many billions of dollars. iTrack Advance seems best suited for this as I'm sure patients would prefer an option that leaves nothing behind if they're getting treated so early on.